MetaCap

Vistagen Therapeutics Inc. (VTGN)

NASDAQ: VTGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.1636-0.023 (-12.33%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

VTGN stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.36
52-week range
0.16 – 5.14
Day range
0.1635 – 0.1915
Volume / Avg
908.86K / 10.30M
Beta
—

52-week range

$0.16$5.14

VTGN stock today

On Nov 20, VTGN ended the session at $0.1636, shedding $0.023 (12.33%), versus the S&P 500's 3.70% decline. Trading was light, with 908.86K shares changing hands, about 9% of the average daily volume. Shares are 96.8% below their 52-week high of $5.14, set on Nov 24, 2025 and 2.2% above the 52-week low of $0.16, near the bottom of the past year's range.

VTGN is down 75.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 96.4%. Vistagen Therapeutics has posted a net loss over the last twelve months (EPS of -$1.36), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Vistagen Therapeutics

Company profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Shawn K. Singh J.D.
Headquarters
South San Francisco, CA
Employees
41

Financial highlights

Full financials

In fiscal 2026, Vistagen Therapeutics generated $1.3 million in revenue, up 161.1% from fiscal 2025. Vistagen Therapeutics reported a net loss of $69.7 million, compared with a loss of $51.4 million a year earlier. Operating margin was -5683.7%.

Vistagen Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue$1.27M$486.00K$1.06M$-227.00K$1.11M
Growth+161.11%-54.32%+568.72%-120.47%+1.79%
Net income$-69.69M$-51.42M$-29.36M$-59.25M$-47.76M
EPS (diluted)$-1.83$-1.67$-1.52$-8.51—

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$1.00+511.25%

  • Strong buy 0
  • Buy 0
  • Hold 4
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.24 vs $-0.37
Surprise
+35.14%

VTGN news

All VTGN news

Vistagen Therapeutics peers

Health Care sector
VTGN peer companies
CompanyPrice% ChgMarket capCompare
RKTORocket One Inc.0.297+5.24%$7.39Mvs VTGN
PHIOPhio Pharmaceuticals Corp.0.656-8.25%$7.84Mvs VTGN
IMRNImmuron Limited ADR0.8998+5.80%$7.26Mvs VTGN
CLRBCellectar Biosciences Inc.0.797-11.50%$8.00Mvs VTGN
DAREDare Bioscience Inc.0.4074-9.87%$8.01Mvs VTGN
CVKDCadrenal Therapeutics Inc.1.70+0.59%$7.01Mvs VTGN
ENSCEnsysce Biosciences Inc.0.36-0.17%$7.00Mvs VTGN
TCRTAlaunos Therapeutics Inc.1.66+3.75%$6.99Mvs VTGN

Indexes, lists and sector

Vistagen Therapeutics stock FAQ

What is Vistagen Therapeutics's stock price today?

VTGN last traded at $0.1636 as of Nov 20, 4:00 PM EST, down 12.33% on the day. Prices are delayed at least 15 minutes.

Does Vistagen Therapeutics pay a dividend?

No. Vistagen Therapeutics does not currently pay a regular cash dividend.

Who is Vistagen Therapeutics's CEO?

Mr. Shawn K. Singh J.D. is the chief executive officer of Vistagen Therapeutics Inc., which has about 41 employees.

Has VTGN ever split its stock?

Yes. The most recent VTGN stock split was a 1-for-30 split on Jun 7, 2023, one of 2 splits on record.

What is the VTGN 52-week high?

The 52-week high for VTGN is $5.14 and the 52-week low is $0.16. The stock is currently 96.8% below its high.

Compare VTGN